Trading at $34, VKTX could explode higher again. That is, if the company sees further positive results with its obesity trials. Most recently, VKTX initiated its VANQUISH Phase 3 clinical program for VK2735, the company's dual agonist of the...
Severely oversold shares of Oracle (ORCL) are showing big signs of life. After gapping lower on AI data center spending fears, Oracle appears to have caught strong support at $188.65. It’s also overextended on RSI, MACD, and Williams’ %R. From here, we’d like to see...
Shares of Amazon (NASDAQ: AMZN) are showing big signs of life again. For one, OpenAI is in talks with the e-commerce giant about an investment that could exceed $10 billion. It could also include an agreement to use Amazon AI chips, too. This comes not long after...
by Ian Cooper Gold is hitting record highs. And there’s still further upside ahead. Just days after the Federal Reserve cut interest rates by another quarter point, Philadelphia Federal Reserve President Anna Paulson says unemployment is a bigger economic threat than...
Since peaking in October, Strategy (MSTR) plummeted from $360 to a low of $162. All thanks to Bitcoin, which fell from about $125,000 in October to a recent low of $87,256. All on fears of fewer interest rate cuts from the Federal Reserve in 2026. However, despite the...
Broadcom took a massive hit late last week, falling $46.44 on Friday. All after management warned of margin pressures. Broadcom posted strong earnings and gave a strong forecast. Unfortunately, the stock fell “after the chipmaker warned growing sales...
Gold is hitting record highs. And there’s still further upside ahead. Just days after the Federal Reserve cut interest rates by another quarter point, Philadelphia Federal Reserve President Anna Paulson says unemployment is a bigger economic threat than inflation,...
At the moment, Oracle (ORCL) is a falling knife. So, we wouldn’t buy just yet. What we’re now waiting to see is if ORCL can hold prior support at $193.60. If it fails at that point, it could slip to $180 worst case. Instead of rushing to...
We’ve been pounding the table over obesity drug stocks for quite some time. Look at Structure Therapeutics (GPCR). The first time we highlighted an opportunity in the stock, it traded at around $22 in late June. Today, it’s up to $66.40 after it unveiled the topline...
by Ian Cooper Shares of Sandisk (SNDK) are still taking off. In fact, according to analysts at Bank of America, the stock could test $300 thanks to growing demand from data centers and artificial intelligence. Fueling further potential upside, the NAND market could...